| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006849305 |
| P356 | DOI | 10.1007/S10549-013-2587-X |
| P698 | PubMed publication ID | 23780683 |
| P5875 | ResearchGate publication ID | 239948249 |
| P2093 | author name string | Frédérique Penault-Llorca | |
| Patricia de Cremoux | |||
| Lise Roca | |||
| Véronique Diéras | |||
| Pierre Kerbrat | |||
| Henri Roché | |||
| Marc Spielmann | |||
| Anne-Laure Martin | |||
| Jean-Luc Canon | |||
| Laurent Cany | |||
| Jérôme Lemonnier | |||
| Emmanuelle Lappartient | |||
| Christel Mesleard | |||
| Stéphanie Chieze | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy | Q27851876 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility | Q28239961 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| A putative molecular-activation switch in the transmembrane domain of erbB2. | Q30476898 | ||
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 | ||
| First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H | Q33533553 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. | Q34428153 | ||
| Gene-expression signatures in breast cancer | Q34948421 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone | Q36006440 | ||
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 | ||
| Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients | Q37292031 | ||
| A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease | Q37371654 | ||
| Interindividual variability of response to rituximab: from biological origins to individualized therapies | Q37826285 | ||
| Gene expression profiling in breast cancer: classification, prognostication, and prediction | Q37958156 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma | Q40562102 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| The neu oncogene encodes an epidermal growth factor receptor-related protein | Q42812960 | ||
| A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients | Q43060768 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 | ||
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells | Q43760313 | ||
| Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects | Q44179953 | ||
| Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. | Q44239907 | ||
| Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody | Q45396762 | ||
| FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. | Q45949257 | ||
| Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial | Q46839548 | ||
| Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. | Q51716563 | ||
| Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. | Q53412908 | ||
| FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer | Q54630456 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 789-800 | |
| P577 | publication date | 2013-06-19 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial | |
| P478 | volume | 139 |
| Q36139709 | Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. |
| Q55208199 | CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. |
| Q28081385 | Cardiac risk in the treatment of breast cancer: assessment and management |
| Q39078275 | Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. |
| Q36413979 | FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer |
| Q57466758 | Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer |
| Q51816225 | Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. |
| Q54111164 | Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies. |
| Q89802710 | Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity |
| Q37709365 | IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). |
| Q38778546 | Pharmacogenetic Predictors of Response |
| Q38358816 | Pharmacogenetics and breast cancer management: current status and perspectives |
| Q50089138 | Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review |
| Q58607138 | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| Q91637215 | Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer |
| Q37688976 | The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer |
| Q39163356 | Trastuzumab-associated cardiac events in the Persephone trial |
Search more.